Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

British journal of cancer - 16 Jul 2007

Ueno H, Kiyosawa K, Kaniwa N

Abstract excerpt

Gemcitabine is a deoxycytidine analogue that has a broad spectrum of antitumour activity in many solid tumours including pancreatic cancer. We have recently carried out a pharmacogenomic study in cancer patients treated with gemcitabine, and found that one genetic polymorphism of an enzyme involv...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antimetabolites, Antineoplastic
Share to Deoxycytidine
Share to DNA Repair

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Enzymes

Share to Gemcitabine

Share to Genomics

Share to Nucleoside Transport Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 17595663
DOI: 10.1038/sj.bjc.6603860
PMCID: PMC2360307

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17595663-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?PMID 17595663Read ↗

Clinical pharmacology and pharmacogenetics of gemcitabineSemantic proximity Read ↗

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.Semantic proximity Read ↗

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.Semantic proximity Read ↗

Integrating pharmacogenetics into gemcitabine dosing—time for a change?Semantic proximity Read ↗

Pharmacogenomics of Gemcitabine in Non-Small-Cell Lung Cancer and Other Solid TumorsSemantic proximity Read ↗

Genetic variations associated with gemcitabine treatment outcome in pancreatic cancerSemantic proximity Read ↗

Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.Semantic proximity Read ↗

Discovery of genetic profiles impacting response to chemotherapy: application to gemcitabine.Semantic proximity Read ↗

Pharmacogenetics of anticancer drug sensitivity in pancreatic cancerSemantic proximity Read ↗

Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.Semantic proximity Read ↗

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Semantic proximity Read ↗

Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.